0647 GMT - Bayer reported strong results for the second quarter and reiterated its full-year guidance, which should be well received by investors, analysts at J.P. Morgan say in a research note. The German agriculture and pharmaceutical conglomerate reported quarterly sales and adjusted earnings that exceeded consensus expectations, and its crop-sciences and pharma divisions--the group's biggest--both beat forecasts, the analysts say. Bayer also reiterated its annual outlook at constant currency and, given that consensus estimates currently sit below the company's guidance, analysts could raise their expectations as a result, JPM says. Bayer shares are likely to outperform Tuesday, the analysts add.